About this trial
This is a multicentre, randomised, phase III trial comparing the efficacy and toxicity of standard 1st line systemic therapy for breast cancer (BC) patients with or without the addition of stereotactic ablative body radiation therapy (SABR) to all the oligometastatic sites. Oligometastatic breast cancer (OMBC) is defined as the presence of 1-5 metastasis in up to 2 organs in the body.
Patient Profile
This study is for men and women over the age of 18 who have a histologically (tissue sample) or cytological (fluid sample) confirmed recurrent/de novo OMBC. OMBC is idefined as 1 – 5 metastases in a maximum of two organs. Patients already on 1st line systemic treatment can be enrolled if repeated tumour evaluations show stable disease.
Where’s this trial being run?
St Luke’s Radiation Oncology Network @ St Luke’s Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.
Print this pageFor more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA) |
|---|---|
| Number: | 22-16 |
| Full Title: | Treatment of oligometastatic breast cancer – a randomised phase III trial comparing stereotactic ablative radiotherapy (SABR) and systemic treatment with systemic treatment alone as first line treatment. |
| Principal Investigator: | Prof Frances Duane |
|---|---|
| Type: | Collaborative |
| Sponsor: | Swedish Association of Breast Oncologists (SABO) |
| Recruitment Started: |
Global: Q3 2022 Ireland: |
| Global Recruitment Target: | 386 |
|---|---|
| Ireland Recruitment Target: | 45 |